Jean George is a general partner with Lightstone Ventures and a managing director at Advanced Technology Ventures (ATV) and LSV Capital Management. She has appeared on the Forbes’ Midas List in the past and has been recognised for her efforts as one of the top women in her field.
Her investment interests focus on companies in the biopharmaceutical and medical device sectors, such as Acceleron Pharma, Calithera Biosciences, Five Prime Therapeutics, Hydra Biosciences, Hypnion (acquired by Eli Lilly) and Proteolix (acquired by Onyx Pharmaceuticals).
Jean has worked in the biopharmaceutical industry for over 20 years. Prior to joining ATV in 2002, she was a director at BancBoston Ventures. Before entering venture capital, she worked in marketing, product development, and business development at Genzyme Corporation, ultimately assuming the position of Vice President of Global Sales and Marketing. She was also the vice president and founder of Genzyme’s Tissue Repair department.
Jean is currently a director at Calithera Biosciences, Hydra Biosciences, Inc., Zeltiq Aesthetics, Inc. and Portola Pharmaceuticals, Inc and used to be a director of Hypnion, Inc., Critical Therapeutics, Inc. and Proteolix, Inc.
She is on the Scientific Advisory Board for the Massachusetts Life Sciences Center.
Jean has a bachelor’s in biology from the University of Maine and an MBA from Simmons College Graduate School of Management.Tags: biotechnology, VC, Women in VC